Search results for "Caspofungin"

showing 10 items of 30 documents

Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study

2022

INTRODUCTION: Intra-abdominal infections represent the second most frequently acquired infection in the intensive care unit (ICU), with mortality rates ranging from 20% to 50%. Candida spp. may be responsible for up to 10-30% of cases. This study assesses risk factors for development of intra-abdominal candidiasis (IAC) among patients admitted to ICU. METHODS: We performed a case-control study in 26 European ICUs during the period January 2015-December 2016. Patients at least 18 years old who developed an episode of microbiologically documented IAC during their stay in the ICU (at least 48 h after admission) served as the case cohort. The control group consisted of adult patients who did no…

Microbiology (medical)MORTALITYInvasive candidiasiCandida; Intra-abdominal infection; Invasive candidiasis; Risk factorsCONTROLLED-TRIALCASPOFUNGINCANDIDEMIAInvasive candidiasisInfectious Diseaseslnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Intra-abdominal infectionRisk factorsINFECTIONSMANAGEMENTEPIDEMIOLOGYPREDICTORSCONSENSUSCRITICALLY III PATIENTSCandida
researchProduct

Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin

2007

ABSTRACT We compared the caspofungin (CAS) susceptibility testing results generated by the disk diffusion (DD) assay with the results of the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BD) reference method for 106 yeast isolates. The isolates represented 11 different fungal species, including Candida albicans ( n = 50), C. parapsilosis ( n = 10), C. glabrata ( n = 10), C. tropicalis ( n = 10), C. guillermondii ( n = 6), C. rugosa ( n = 5), C. krusei ( n = 5), C. kefyr ( n = 2), C. pelliculosa ( n = 2), Saccharomyces cerevisiae ( n = 3), and Geotrichum candidum ( n = 3). The DD assay was performed in supplemented Mueller-Hinton agar with CAS, which was tested at c…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaSusceptibility testingAntifungal AgentsInhibition zonefood.ingredientGeotrichumMicrobial Sensitivity TestsMycologyMicrobiologyDiffusionEchinocandinsLipopeptideschemistry.chemical_compoundfoodCaspofunginCandida albicansAgarCandida albicansCaspofungin Candida Disk diffusion antimicrobial testingbiologyBroth microdilutionFungibiology.organism_classificationYeastchemistryCaspofunginJournal of Clinical Microbiology
researchProduct

International Multicentre Study of Candida auris Infections

2021

Background:Candida auris has emerged globally as a multi-drug resistant yeast and is commonly associated with nosocomial outbreaks in ICUs. Methods: We conducted a retrospective observational multicentre study to determine the epidemiology of C. auris infections, its management strategies, patient outcomes, and infection prevention and control practices across 10 centres from five countries. Results: Significant risk factors for C. auris infection include the age group of 61–70 years (39%), recent history of ICU admission (63%), diabetes (63%), renal failure (52%), presence of CVC (91%) and previous history of antibiotic treatment (96%). C. auris was commonly isolated from blood (76%). Echi…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialtyEchinocandinC. auris Candida Fungi Nosocomial Outbreak ResistanceQH301-705.5Plant ScienceEmergenceresistancechemistry.chemical_compound<i>C. auris</i>Internal medicine<p>C. auris</p>EpidemiologymedicineInfection controlBiology (General)Ecology Evolution Behavior and SystematicsCandidaoutbreakbusiness.industryMortality rateMicafunginnosocomialResistantManagement<i>Candida</i>chemistryCandida aurisAnidulafunginfungiCaspofunginbusinessmedicine.drug
researchProduct

Evaluation of the Disk Diffusion Method Compared to the Microdilution Method in Susceptibility Testing of Anidulafungin against Filamentous Fungi

2008

ABSTRACT Susceptibility testing of anidulafungin (AFG) against 32 mold isolates showed an excellent correlation between disk diffusion (DD) and broth microdilution methods. Based on our data, a 2-μg disk of AFG and a 24-h reading time might represent the best parameters for AFG DD testing against filamentous fungi.

Microbiology (medical)Susceptibility testingAntifungal AgentsDisk Diffusion; Yeasts; CaspofunginDisk diffusion anidulafungin MIC MECMycologyMicrobial Sensitivity TestsBiologyAnidulafunginSettore MED/42 - Igiene Generale E ApplicataDisk DiffusionMicrobiologyEchinocandinsCaspofunginYeastsmedicineHumansAgar diffusion testFood scienceAspergillus Anidulafungin Disk Diffusion1 3 β glucan synthaseAnidulafungineBroth microdilutionFungiAnidulafunginaMycosesAnidulafunginmedicine.drugJournal of Clinical Microbiology
researchProduct

Pga26 mediates filamentation and biofilm formation and is required for virulence in Candida albicans

2011

The Candida albicans gene PGA26 encodes a small cell wall protein and is upregulated during de novo wall synthesis in protoplasts. Disruption of PGA26 caused hypersensitivity to cell wall-perturbing compounds (Calcofluor white and Congo red) and to zymolyase, which degrades the cell wall β-1,3-glucan network. However, susceptibility to caspofungin, an inhibitor of β-1,3-glucan synthesis, was decreased. In addition, pga26Δ mutants show increased susceptibility to antifungals (fluconazol, posaconazol or amphotericin B) that target the plasma membrane and have altered sensitivities to environmental (heat, osmotic and oxidative) stresses. Except for a threefold increase in β-1,6-glucan and a sl…

MutantCellBiofilmVirulenceGeneral MedicineCalcofluor-whiteBiologybiology.organism_classificationApplied Microbiology and BiotechnologyMicrobiologyMicrobiologyCell wallchemistry.chemical_compoundmedicine.anatomical_structurechemistrymedicineCaspofunginCandida albicansFEMS Yeast Research
researchProduct

Posaconazole concentrations in the central nervous system

2008

more susceptible to the killing activity of caspofungin. This study is the first comparing caspofungin killing activity against the closely related species C. parapsilosis, C. orthopsilosis and C. metapsilosis. Killing curves, regardless of the medium used, showed a decreasing order of susceptibility to caspofungin: C. metapsilosis . C. orthopsilosis . C. parapsilosis. Based on high echinocandin MICs for C. parapsilosis sensu stricto, in the case of isolates identified as C. parapsilosis sensu lato low MICs of echinocandins may be regarded as an indicator that an isolate is in fact C. orthopsilosis or C. metapsilosis; in the case of isolates with low echinocandin MICs, DNA-based identificat…

PharmacologyMicrobiology (medical)PosaconazoleEchinocandinBiologyPharmacologybacterial infections and mycosesBiological fluidMicrobiologychemistry.chemical_compoundInfectious Diseaseschemistryparasitic diseasespolycyclic compoundsTriazole derivativesmedicinePharmacology (medical)CaspofunginEchinocandinsSensu strictoSerum chemistrymedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Dose Escalation of Caspofungin for Invasive Aspergillosis - A Phase II Trial

2010

Abstract Abstract 2309 Objectives. Treatment of invasive aspergillosis (IA) fails in up to 50% of all cases and the mortality rate is at least 30%. Antifungal combination treatment has not been proven to be beneficial and dose escalation with liposomal amphotericin B did not improve outcome. New approaches are needed for patients with severe immunosuppression. Methods. Escalating high dosages of caspofungin were investigated in IA defined according to modified EORTC/MSG criteria. The tested cohort of patients received 70mg, 100mg, 150mg or 200mg QD, 8 patients each were to receive caspofungin first-line treatment for proven/probable IA for up to 28 days. Dose limiting toxicity was defined a…

Voriconazolemedicine.medical_specialtyDosebusiness.industryMortality rateImmunologyCell BiologyHematologyAspergillosismedicine.diseaseBiochemistrySurgerychemistry.chemical_compoundchemistryInternal medicineToxicityCohortmedicineCaspofunginAdverse effectbusinessmedicine.drugBlood
researchProduct

Successful Topical Application of Caspofungin in the Treatment of Fungal Keratitis Refractory to Voriconazole

2010

Fungal keratitis is an important ophthalmic problem because it leads to corneal blindness and sometimes to loss of the eye.1,2 There is no agreed protocol for the treatment of suspected fungal keratitis. Topical and oral voriconazole have now been reported to be effective.3 However, some cases do not respond to this treatment. New antifungal agents such as caspofungin acetate, 0.5%, are promising alternatives

Voriconazolemedicine.medical_specialtybusiness.industryEye diseaseFongs patògensmedicine.diseasecorneal ulcerCaspofungin AcetateKeratitisSurgeryOphthalmologychemistry.chemical_compoundRefractorychemistrymedicineFungal keratitisCaspofunginbusinessmedicine.drugArchives of Ophthalmology
researchProduct

Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital se…

2007

As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable…

medicine.medical_specialtyAntifungal AgentsLiposomal amphotericin Blaw.inventionNephrotoxicitychemistry.chemical_compoundEchinocandinsLipopeptidesRandomized controlled trialDouble-Blind MethodlawCaspofunginBottom-up studyAmphotericin BInternal medicineAmphotericin BGermanymedicineHumansLongitudinal StudiesProspective StudiesProspective cohort studyIntensive care medicineNephrotoxicitybusiness.industryGeneral MedicineHematologybacterial infections and mycosesConfidence intervalEconomic evaluationchemistryMycosesLiposomesNumber needed to treatCosts and Cost AnalysisObservational studyOriginal ArticleCaspofunginbusinessmedicine.drugAnnals of Hematology
researchProduct

Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease

2011

The aim of this study was to evaluate micafungin efficacy for treatment of invasive candidiasis/candidaemia in patients with cancer. Modified intent-to-treat populations were analysed from two trials: one, in adults and children with confirmed Candida infection, compared micafungin (adults 100 mg day(-1); children 2 mg kg(-1) day(-1)) with liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1)); and the other, in adults only, compared micafungin (100 or 150 mg day(-1)) with caspofungin (50 mg day(-1); 70 mg loading dose). Primary efficacy endpoint in both trials was treatment success, defined as both clinical and mycological response at end of therapy. In the micafungin/L-AmB trial, 183/489 pa…

medicine.medical_specialtybusiness.industryMicafunginDermatologyGeneral MedicineNeutropeniabacterial infections and mycosesmedicine.diseaseMalignancyLoading doselaw.inventionSurgeryClinical trialchemistry.chemical_compoundInfectious DiseaseschemistryRandomized controlled triallawInternal medicinemedicineCaspofunginAdverse effectbusinessmedicine.drugMycoses
researchProduct